These results are consistent with and strongly support the major tenet of the ACH2.0, namely that iAβ, produced in AD mainly in the AβPP-independent pathway, triggers and drives the neurodegeneration and that its depletion would be therapeutically beneficial. The gene discussed is APP; the disease is Alzheimer disease.